Organisation paid for research Program year 2025 Source: CMS Open Payments

Chas Spokane Pediatrics

Neither a doctor nor a teaching hospital

Research payments

$22,002

102 payments

Through program year 2025, Chas Spokane Pediatrics is reported as receiving $22,002 in research payments, across 102 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $5,127 94
2024 Research $10,594 6
2023 Research $6,281 2

Breakdown

Who paid Research payments · program years 2023–2025
  1. Boehringer Ingelheim International GmbH $18,295 97 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $3,708 5 payments
Studies the money was for Research payments · program years 2023–2025
  1. Obesity Long term safety in patients with CV risk $16,875 8 payments
  2. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $5,127 94 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record